September 2026– date –
-
Pin Therapeutics Unveils Oral CK1α Molecular Glue Degrader PIN-5018 for Adenoid Cystic Carcinoma at China TPD Forum, Phase 1 Underway Targeting FDA Accelerated Approval
Korea Biomedical Review South Korea Overview Pin Therapeutics presented PIN-5018, an oral CK1α-selective molecular glue degrader for adenoid cystic carcinoma (ACC), derived from its proprietary PinMARS platform, at the China Targeted Pro... -
Oligonucleotide Drug Delivery Shifts Beyond Liver-Targeting to Tissue-Specific Approaches for Muscle and CNS
GlobeNewswire Unknown Overview Oligonucleotide drug delivery is evolving significantly, moving from traditional liver-targeted strategies to tissue-specific approaches for extrahepatic organs like muscle and the central nervous system (C... -
Oral Absorption of Therapeutic Peptides Remains Below 1%, MDPI Review Identifies Enzymatic Degradation, pH, Microbiota as Key Barriers
MDPI Unknown Overview A new MDPI review provides a comprehensive analysis of the complex physiological determinants influencing the oral absorption of therapeutic peptides. It confirms that the bioavailability of oral peptides typically ... -
Clinical Landscape of Targeted Protein Degradation Explored, Molecular Glues Show Faster Progress with Nanomedicine Delivery Strategies
MDPI Unknown Overview A new review analyzes the clinical landscape of targeted protein degradation (TPD), focusing on PROTACs and molecular glue degraders, noting that the smaller molecular size of molecular glues may enable faster clini... -
University of Virginia Pioneers Focused Ultrasound for Temporary Blood-Brain Barrier Opening, Redefining Drug Size Impact on Delivery
Physics World USA Overview Researchers at the University of Virginia have developed a pioneering method using focused ultrasound (FUS) to temporarily open the blood-brain barrier (BBB) for drug delivery to the brain. Utilizing MRI physic... -
Nanotechnology Overcomes Drug Delivery Challenges: Liposomes & Polymeric Nanoparticles Enhance Drug Solubility and Targeted Delivery
Scientific Review Unknown Overview A recent review highlights nanotechnology's transformative role in overcoming traditional drug delivery challenges, such as poor solubility and non-specific distribution. Diverse nanocarriers, including... -
Chemoenzymatic Ligation Offers Scalable Solution to Nucleic Acid Therapeutics Manufacturing Bottlenecks, Surpassing Solid-Phase Synthesis Limits
The Medicine Maker Unknown Overview A new chemoenzymatic ligation technology is emerging as a scalable solution to the manufacturing bottlenecks in nucleic acid therapeutics, such as siRNA and mRNA. This approach efficiently assembles ol... -
Widespread GLP-1 Agonist Use Reduces US Adult Obesity Rate by 2% (2022-2025); WHO Recognizes Obesity as Chronic Disease
LinkedIn USA Overview Widespread adoption of GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro, Zepbound) has correlated with a 2% reduction in the US adult obesity rate between 2022 and 2025. This impact is reinforced by ongoing Phase ... -
Viking Therapeutics Initiates Phase 2 VENTURE-Oral Trial for Oral Dual GLP-1/GIP Agonist VK2735 in Obesity
Superpower USA Overview Viking Therapeutics has commenced its Phase 2 VENTURE-Oral trial in early 2025 for VK2735, an oral dual GLP-1/GIP receptor agonist targeting obesity. This move highlights the intense competition in the metabolic d... -
CDMO Curia Massively Expands Sterile Fill-Finish Capacity in UK, US for Biologics and ADCs
Packaging Digest UK, USA Overview CDMO Curia has significantly expanded its sterile fill-finish manufacturing facilities in Glasgow, UK, and Albuquerque, US, to meet surging demand for biologics and highly potent antibody-drug conjugates...
